| Literature DB >> 31838735 |
Mona Oliveira1,2, Lourenço Luis Botelho de Santana3,4, José Claudio Serafim3,4, Airam Oliveira Santos3, Michelle Pereira Quintino3,4, José Tiago Menezes Correia3, Fabiano Damasceno3, José Ricardo Sabino5, Thiago Rubens Cardim Pires1,2, Paulo Lucas Cerqueira Coelho1,2, Giselle Pinto de Faria Lopes1,6, Henning Ulrich7, Silvia Lima Costa8,9, Silvio Cunha10,11.
Abstract
Twelve multi-functional pyrrolizidinones, indolizidinones and pyrroliazepinones were prepared from formal aza-[3 + 2] and aza-[3 + 3] cycloadditions of five- to seven-membered heterocyclic enaminones as diverse ambident electrophiles. The antitumor activity of these alkaloid-like compounds was investigated through an initial screening performed on human glioblastoma multiform (GBM) cell lines (GL-15, U251), on murine glioma cells line (C6) and on normal glial cells. Of the compounds tested, the new pyrrolo[1,2a]azepinone, [ethyl (3-oxo-1,2-diphenyl-6,7,8,9-tetrahydro-3H-pyrrolo[1,2a]azepin-9a(5H)-yl)acetate] or (Compound-13) exhibited selective cytotoxic effects on GBM-temozolomide resistant cells. Compound-13 exerted dose-dependent cytotoxic activity by promoting arrest of cells in the G0/G1 phase of the cell cycle in the first 24 h. The apoptotic effect observed was in a time-dependent manner. Anti-migratory effect promoted by the treatment with compound-13 was also observed. Moreover, healthy mixed glial cell cultures from rat brain exhibited no cytotoxicity effect upon exposure to compound-13. Thus, the present study paves the way for the use of compound-13 as novel antitumor scaffold candidate for glioma cell therapy.Entities:
Keywords: Anti-tumor agent; Azabicyclic compounds; Chemoresistance; Formal aza-cyclo additions; Glioblastoma cells
Year: 2019 PMID: 31838735 DOI: 10.1007/s10637-019-00877-2
Source DB: PubMed Journal: Invest New Drugs ISSN: 0167-6997 Impact factor: 3.850